CVS Health Corp (NYSE:CVS) shares are trading higher Tuesday morning after the Centers for Medicare & Medicaid Services finalized 2027 Medicare Advantage and Part D payment policies that point to higher overall funding for the sector while tightening certain risk-adjustment rules. Here’s what investors need to know.

CMS Payment Increase Puts Medicare Advantage Economics Back In Focus

CMS said the changes are projected to drive a net average 2.48% increase, or more than $13 billion in additional Medicare Advantage payments in calendar 2027.

For CVS, the update matters because the company is more than just a drugstore chain. Through its Aetna insurance unit, CVS is a major managed-care player with exposure to Medicare Advantage, while also operating one of the country's largest pharmacy benefit managers and a nationwide retail pharmacy and healthcare-services network.

That makes policy changes in government-backed health plans especially relevant to its earnings outlook.

Risk-Adjustment Changes Add A More Nuanced Read For Insurers

Investors appear to be focusing on the funding boost, which could help support reimbursement levels across Medicare Advantage plans. At the same time, CMS said it will continue using the 2024 Medicare Advantage risk-adjustment model for 2027 and will exclude diagnoses from unlinked chart reviews from risk-score calculations in most cases.

That could create a more mixed read for insurers that leaned heavily on coding-driven reimbursement. Even so, for a diversified company like CVS, traders may be viewing the headline increase in Medicare Advantage payments as the bigger near-term catalyst for sentiment Tuesday morning.

CVS Investors Look Ahead To May 6 Earnings Report

Following last quarter’s results, investors are now tracking the path toward the next reporting date on May 6.

  • EPS Estimate: $2.23 (Down from $2.25 YoY)
  • Revenue Estimate: $94.86 Billion (Up from $94.59 Billion YoY)
  • Valuation: P/E of 52.7x (Indicates premium valuation relative to peers)

Analysts Keep Bullish Bias On CVS Despite Target Cuts

Analyst Consensus & Recent Actions: The stock carries a Buy Rating with an average price target of $92.79. Recent analyst moves include:

  • Piper Sandler: Overweight (Lowers Target to $99.00) (March 31)
  • Bernstein: Upgraded to Outperform (Raises Target to $94.00) (March 12)
  • Argus Research: Buy (Lowers Target to $90.00) (Jan. 28)

CVS Shares Climb Tuesday Morning

CVS Price Action: CVS Health shares were up 3.67% at $75.97 at the time of publication on Tuesday, according to Benzinga Pro data.

Image: Shutterstock